Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report
© Preidl et al.; licensee BioMed Central Ltd. 2014
Received: 13 June 2013
Accepted: 3 January 2014
Published: 8 January 2014
Bisphosphonates have a widespread indication for osteoporosis and are also applied in cancer patients with skeletal-related conditions. Bisphosphonate-associated osteonecrosis of the jaw (BRONJ) is a feared side effect which is hard to treat and often affects patient´s quality of life in an extensive manner. Adalimumab (Humira®), a fully human recombinant antibody specific for tumor necrosis factor- α, is approved for treatment in patients with Inflammatory Bowel Disease like ulcerative colitis or Crohn’s disease.
In March 2013, a 36-year-old female presented with right-sided perimandibular swelling, recurrent facial pain and exposed necrotic bone after previous extraction of tooth 47. She had the medical history of Crohn’s disease for more than one decade with chronic active enterocolitis, fistula disease as well as previous oral manifestation and was currently treated with Adalimumab since September 2008. Due to steroid-induced osteoporosis, diagnosed in 2004, she received oral Bisphosphonates (Risedronate) from 2004 until 2007 followed by two infusions of Zoledronic acid in 2008 and 2009.
This patient with a medical history of Crohn’s disease and gastrointestinal remission under Adalimumab therapy presented with osteonecrosis of the jaw after suspended oral and intravenous Bisphosphonate therapy implicating that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity.
KeywordsOsteonecrosis of the jaw Bisphosphonate Adalimumab Crohn’s disease
Bisphosphonates are primarily applied in patients with skeletal complications associated with osteoporosis as well as malignancy [1, 2]. Bisphosphonate–associated osteonecrosis of the jaw (BRONJ), first described in 2003, poses a serious complication in patients currently or previously treated with Bisphosphonates and is associated with exposed bone in the maxillofacial region for at least 8 weeks without any radiotherapy of the jaw in the past [3, 4]. The occurrence of BRONJ not only depends on the duration of the BP therapy but also varies between oral and intravenous application with far more cases reported after intravenous infusions with a cumulative incidence of 0,8%- 12% [5, 6]. Although the pathomechanism is not yet completely understood, there are local risk factors like extraction of teeth, placement of dental implants, periapical surgery or dental abscesses going along with an increased incidence of osteonecrosis . Beyond this, genetic and drug- related factors influence the appearance of BRONJ . Clinically BRONJ presents as non-vital, exposed bone that might go along with inflammatory reactions due to secondary infection and therefore the gingival or mucosal tissue is usually sensitive to palpation. This process can aggravate to bone sequestration going along with acute osteomyelitis resulting in spreading and increased mobility of additional teeth . Presumably, BRONJ is associated with infection and therefore immune-modulating drugs, as applied in patients with Crohn’s disease or rheumatoid arthritis, might be an important risk factor in the development of necrotic lesions in the jaw [10, 11]. We already know that not only Bisphosphonates but also Denosumab or other biologicals are under suspicion to promote or even cause necrotic lesions in the jaw [12, 13]. To our knowledge there is currently no published case of BRONJ in a patient with Crohn’s disease also affecting the oral cavity and treated with Adalimumab.
Aminobisphosphonates are well established in the therapy of osteoporosis and metastatic cancer disease. Although BRONJ is a serious adverse event especially after intravenous administration, Aminobisphosphonates improve cancer control and increase long-term survival. This case report presents an extraordinary course of osteonecrosis of the jaw after mainly oral Bisphosphonate therapy and application of Adalimumab in a Crohn’s disease patient affecting almost the whole gastrointestinal tract. Bisphosphonates can cause gastrointestinal mucosal injuries and reduce bone remodelling by predominantly inhibiting osteoclasts via RANKL. Furthermore these drugs seem to have anti-angiogenic effects contributing to impaired wound-healing for example after tooth extraction [15, 16].
Adalimumab, representing a fully humanised anti-TNF-α antibody, is an established biologic agent in the treatment of Crohn’s disease with proven clinical benefits . Unfortunately there are already some reports about serious adverse effects like new-onset of multiple sclerosis, psoriasiform lesions, lupus like syndrome and infectious complications including sepsis in patients treated with the agent [18, 19].
Cases of osteonecrosis in extracranial bones like the femur or the talus in patients with Inflammatory Bowel Disease and long lasting corticoid therapies have already been published [20, 21]. Some even maintain that avascular osteonecrosis might be an extraintestinal manifestation of Inflammatory Bowel Disease although in some cases the interval between steroid treatment and avascular bone necrosis was quite extended [22, 23]. However, in this report we present the first case of osteonecrosis in the jaw with the underlying history of Crohn’s disease being currently treated with Adalimumab (Humira®) which can be seen in a certain correlation to other cases demonstrating patients with osteonecrosis of the jaw and biological anti-TNF-α therapy with Infliximab .
The EXTEND trial revealed improved mucosal healing of gastrointestinal tissue under anti-TNF-α therapy , despite this it is still unclear whether anti-TNF-α treatment affects the oral mucosa and/or interferes with bone physiology, bone turnover, local immunity and wound repair on the long run. Pathomechanistically one could speculate at this stage that an inhibitory effect of Adalimumab on bone turnover might be mediated by a reduction of RANKL which could already be shown in patients with rheumatoid arthritis and anti-TNF-α therapy [25, 26]. Interestingly osteonecrotic lesions in the jaw have also been reported within treatment regimes including Denosumab in cancer patients assuming that a blockade of receptor activator of nuclear factor-kappa-B (RANK) and receptor activator of nuclear factor-kappa-B- ligand (RANKL) interaction affects monocytic migration as well as osteoclast function comparable to Bisphosphonates . We already know that Adalimumab induces apoptosis of activated human monocytes . While apoptosis of disease-specific or reactive monocytes may be beneficial in idiopathic Inflammatory Bowel Disease, apoptosis of monocytes activated by infectious agents still present within the oral cavity may worsen wound healing, mucosal repair and bone repair of the jaw after necrosis. However, it still has to be investigated how bone metabolism and local infections surveillance in patients with Inflammatory Bowel Disease is influenced in the long run and how therapeutic strategies including biological substances lead to avascular bone necrosis in the jaw. Especially when considering already observed infectious complications due to immunosuppression associated with Adalimumab application it has to be investigated if osteonecrotic lesions might also occur because of spreading ongoing infections and/or have to be seen within the context of a certain innate immune dysfunction lacking defensin expression [29, 30].
Regarding this case, on-going oral Crohn’s disease might be a confounder in terms of mucosal healing. Although the patient had no gastrointestinal symptoms including aphthous lesions in the oral cavity during Adalimumab- therapy, general oral mucosal healing capacities might be compromised.
Patients with Inflammatory Bowel Disease and planned treatment with biological drugs like Adalimumab and a history of Bisphosphonate therapy should be also clinically investigated by a dentist before prescription of biologicals. Furthermore they should be monitored carefully with regard to osteonecrotic lesions of the jaw especially after dental procedures or within periodontal disease.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Bisphosphonate-associated osteonecrosis of the jaw
Receptor activator of nuclear factor-kappa-B
Receptor activator of nuclear factor-kappa-B- ligand.
We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg within the funding programme Open Access Publishing.
- Kamel HK: Update on osteoporosis management in long-term care: focus on bisphosphonates. J Am Med Dir Assoc. 2007, 8: 434-440. 10.1016/j.jamda.2007.06.005.View ArticlePubMedGoogle Scholar
- Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer. 2008, 98: 1736-1740. 10.1038/sj.bjc.6604382.View ArticlePubMedPubMed CentralGoogle Scholar
- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg. 2009, 67: 2-12.View ArticlePubMedGoogle Scholar
- Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003, 61: 1115-1117. 10.1016/S0278-2391(03)00720-1.View ArticlePubMedGoogle Scholar
- Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS: Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J Oral Maxillofac Surg. 2013, 71: 513-519. 10.1016/j.joms.2012.07.049.View ArticlePubMedGoogle Scholar
- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009, 35: 119-130. 10.1111/j.1747-4477.2009.00213.x.View ArticlePubMedGoogle Scholar
- Marx RE, Cillo JE, Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007, 65: 2397-2410. 10.1016/j.joms.2007.08.003.View ArticlePubMedGoogle Scholar
- Stockmann P, Nkenke E, Englbrecht M, Schlittenbauer T, Wehrhan F, Rauh C, Beckmann MW, Fasching PA, Kreusch T, Mackensen A, et al: Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2013, 41: 71-75. 10.1016/j.jcms.2012.10.018.View ArticlePubMedGoogle Scholar
- Migliorati CA, Siegel MA, Elting LS: Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006, 7: 508-514. 10.1016/S1470-2045(06)70726-4.View ArticlePubMedGoogle Scholar
- Stockmann P, Wehrhan F, Schwarz-Furlan S, Stelzle F, Trabert S, Neukam FW, Nkenke E: Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: an immunohistological study. J Transl Med. 2011, 9: 135-10.1186/1479-5876-9-135.View ArticlePubMedPubMed CentralGoogle Scholar
- Allen MR: Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs. 2009, 189: 289-294. 10.1159/000151371.View ArticlePubMedGoogle Scholar
- Kyrgidis A, Toulis KA: Denosumab-related osteonecrosis of the jaws. Osteoporos Int. 2011, 22: 369-370. 10.1007/s00198-010-1177-6.View ArticlePubMedGoogle Scholar
- Ebker T, Rech J, von Wilmowsky C, Neukam FW, Stockmann P: Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology (Oxford). 2013, 52: 218-220. 10.1093/rheumatology/kes351.View ArticleGoogle Scholar
- Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E: Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer. 2010, 18: 449-460. 10.1007/s00520-009-0688-1.View ArticlePubMedGoogle Scholar
- Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006, 12: 6222s-6230s. 10.1158/1078-0432.CCR-06-0843.View ArticlePubMedGoogle Scholar
- Nagano Y, Matsui H, Shimokawa O, Hirayama A, Nakamura Y, Tamura M, Rai K, Kaneko T, Hyodo I: Bisphosphonate-induced gastrointestinal mucosal injury is mediated by mitochondrial superoxide production and lipid peroxidation. J Clin Biochem Nutr. 2012, 51: 196-203.PubMedPubMed CentralGoogle Scholar
- Dryden GW: Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther. 2009, 9: 967-974. 10.1517/14712590903048909.View ArticlePubMedGoogle Scholar
- Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K: New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol. 2013, 32: 271-275. 10.1007/s10067-012-2113-2.View ArticlePubMedGoogle Scholar
- Joyau C, Veyrac G, Dixneuf V, Jolliet P: Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?. Clin Exp Rheumatol. 2012, 30: 700-706.PubMedGoogle Scholar
- Hauzeur JP, Malaise M, Gangji V: Osteonecrosis in inflammatory bowel diseases: a review of the literature. Acta Gastroenterol Belg. 2009, 72: 327-334.PubMedGoogle Scholar
- Freeman HJ: Osteomyelitis and osteonecrosis in inflammatory bowel disease. Can J Gastroenterol. 1997, 11: 601-606.View ArticlePubMedGoogle Scholar
- Lanyi B, Dienes HP, Kruis W: Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?. Dtsch Med Wochenschr. 2005, 130: 1944-1947. 10.1055/s-2005-872607.View ArticlePubMedGoogle Scholar
- Klingenstein G, Levy RN, Kornbluth A, Shah AK, Present DH: Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther. 2005, 21: 243-249. 10.1111/j.1365-2036.2005.02231.x.View ArticlePubMedGoogle Scholar
- Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, et al: Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012, 142: 1102-1111. 10.1053/j.gastro.2012.01.035. e1102View ArticlePubMedGoogle Scholar
- Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, et al: High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum. 2002, 46: 1744-1753. 10.1002/art.10388.View ArticlePubMedGoogle Scholar
- Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, Garcia-Vicuna R: Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis. 2007, 66: 1675-1678. 10.1136/ard.2007.071910.View ArticlePubMedPubMed CentralGoogle Scholar
- Akhtar NH, Afzal MZ, Ahmed AA: Osteonecrosis of jaw with the use of denosumab. J Cancer Res Ther. 2011, 7: 499-500. 10.4103/0973-1482.92020.View ArticlePubMedGoogle Scholar
- Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005, 21: 251-258. 10.1111/j.1365-2036.2005.02309.x.View ArticlePubMedGoogle Scholar
- Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH: Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010, 25: 1732-1738. 10.1111/j.1440-1746.2010.06407.x.View ArticlePubMedGoogle Scholar
- Gersemann M, Wehkamp J, Stange EF: Innate immune dysfunction in inflammatory bowel disease. J Intern Med. 2012, 271: 421-428. 10.1111/j.1365-2796.2012.02515.x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/14/6/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.